Most importantly, when the inhibitor was combined with immune checkpoint inhibitors, it halted tumor growth. Historically, drug development has focused almost entirely on cancer cells.

However, developing highly selective FGFR2/3 inhibitors and overcoming drug resistance remain two of the most significant challenges in the field.